Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.

Show other versions (1)

BACKGROUND: New vaccines to prevent tuberculosis are urgently needed. MVA85A is a novel viral vector TB vaccine candidate designed to boost BCG-induced immunity when delivered intradermally. To date, intramuscular delivery has not been evaluated. Skin and muscle have distinct anatomical and immunolo...

Descrición completa

Detalles Bibliográficos
Main Authors:	Meyer, J, Harris, SA, Satti, I, Poulton, I, Poyntz, H, Tanner, R, Rowland, R, Griffiths, K, Fletcher, H, Mcshane, H
Formato:	Journal article
Idioma:	English
Publicado:	2013

Títulos similares

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado: (2013)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
por: Harris, S, et al.
Publicado: (2011)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
por: Rowland, R, et al.
Publicado: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
por: Pathan, A, et al.
Publicado: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, A, et al.
Publicado: (2012)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, A, et al.
Publicado: (2011)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
por: Whelan, K, et al.
Publicado: (2009)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
por: Harris, S, et al.
Publicado: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
por: Thomas, Z, et al.
Publicado: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
por: Mcshane, H
Publicado: (2008)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
por: Kathryn T. Whelan, et al.
Publicado: (2011-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
por: Harris, SA, et al.
Publicado: (2014)

Th1/Th17 cell induction following vaccination with the novel tuberculosis vaccine MVA85A and their role in Mycobacterium tuberculosis challenge
por: Griffiths, K, et al.
Publicado: (2011)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
por: Rowland, R, et al.
Publicado: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
por: Riste, M, et al.
Publicado: (2021)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
por: Minhinnick, A, et al.
Publicado: (2016)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Brookes, R, et al.
Publicado: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, A, et al.
Publicado: (2017)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
por: Satti, I, et al.
Publicado: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
por: Satti, I, et al.
Publicado: (2014)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
por: Betts, G, et al.
Publicado: (2012)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
por: Sander, C, et al.
Publicado: (2009)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Roger H Brookes, et al.
Publicado: (2008-08-01)

CD4 T cell response to MVA85A vaccination against Mycobacterium tuberculosis in healthy HIV-infected adults
por: Beveridge, N, et al.
Publicado: (2011)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
por: Tameris, M, et al.
Publicado: (2014)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
por: Hawkridge, T, et al.
Publicado: (2008)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
por: Tameris, M, et al.
Publicado: (2014)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
por: Michael Riste, et al.
Publicado: (2021-04-01)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
por: Gareth Betts, et al.
Publicado: (2012-01-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
por: Roger H. Brookes, et al.
Publicado: (2011-01-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
por: Anne Wajja, et al.
Publicado: (2017-05-01)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
por: Ota, M, et al.
Publicado: (2011)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
por: Ota, M, et al.
Publicado: (2011)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, S, et al.
Publicado: (2015)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.
por: Matsumiya, M, et al.
Publicado: (2014)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
por: Dieye, T, et al.
Publicado: (2013)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, M, et al.
Publicado: (2014)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
por: Mcshane, H, et al.
Publicado: (2005)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
por: Michele Tameris, et al.
Publicado: (2014-01-01)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
por: Wajja, A, et al.
Publicado: (2024)